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OBJECTIVES: In the secondary prevention of cardio-
vascular disease patient compliance with established 
risk-reducing factors remains inadequate. The primary
objective of the ORBITAL Study is to evaluate the impact
of a compliance enhancing program in patients receiving
statin therapy on long-term disease-related outcomes and
costs. Here the design and results of the pilot phases are
presented. METHODS: Approximately 7000 patients 
eligible for statin therapy (Joint European Guidelines) will
be enrolled nationwide in primary care practices in
Germany. Patients will be randomised into an interven-
tion group (12-month rosuvastatin plus compliance
program) and a control group (12-month rosuvastatin
alone). Disease-related costs, quality of life, cardiovascu-
lar events, and compliance will be assessed every 6
months during the 36 months follow-up. The compliance
program was developed based on previous studies, expert
advice, and pilot testing, and includes a start package
with a video and an information brochure, followed by
mailings and telephone calls. The program addresses
factors such as diet and lifestyle in addition to compli-
ance with pharmacotherapy. The information brochure
and telephone calls were evaluated in two subsequent
pilot phases. RESULTS: In the ﬁrst pilot phase, 23 of 25
contacted patients in a cardiac rehabilitation center con-
sidered the brochure to be easy to understand although
some criticized the use of too many medical terms. 17%
of patients considered the brochure to be too long. In 
the second pilot phase, 70 patients were randomised 
into intervention (n = 37) or control (n = 33) groups. The
majority of the intervention patients expressed high sat-
isfaction with the telephone calls although 10% indicated
the calls contained too much information and should be
shortened. CONCLUSION: With regard to the compli-
ance initiatives evaluated, the importance of not over-
loading patients with information became apparent.
Therefore, the compliance enhancing program was
revised accordingly for the main phase of the ORBITAL
Study, which started in May 2002 and is scheduled to run
for 3 years.
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The chronic heart failure (CHF) is a chronic illness typi-
cally characterized by phases of clinical deterioration
requiring hospitalitation. The relief continuity is a fun-
damental element to better the effectiveness of the sani-
tary intervention. The Day-Hospital (DH), particularly,
could represent a valid tool to guarantee the relief conti-
nuity and to extend the phases of clinical stability in
patients with CHF. OBJECTIVES: The aim of this study
was to compare the managerial effectiveness and
Cost/Utility ratio between heart failure management
program delivered by day-hospital and usual care.
METHODS: Two hundred thirty-four consecutive
patients (M/F: 196/38; 56 ± 10 years) with chronic heart
failure (EF 29 ± 7%) referred to UHF were evaluated.
After clinical evaluation and therapuetic optimization,
122 patients received usual care (UC) and follow-up
(control every 6 months), despite 112 patients were acti-
vated in the DH. The DH program foresaw: 1) risk proﬁle
identiﬁcation; 2) objectives deﬁnition; 3) sanitary run
determination; 4) outcome markers measurement; and 5)
territory interaction (physician of family and/ or cardiol-
ogist of reference). Management (optimezed therapy and
Hospital readmission for heart failure (HRHF), func-
tional (NYHA functional class, Left ventricular ejection
fraction (LVEF)) and hard (cardiac death and urgent heart
transplantation) outcomes during 258 ± 88 days of
follow-up were considered. Cost/utility ratio of two
strategies were calculated. RESULTS: At baseline not
clinical and functional differences between two groups
were found. Hard cardiac events occured in 21/122
(17.2% on usual care (UC) and in 4/112 (3.6%) in DH
patients (p < .0007). The cost/utility ratio of two strate-
gies was similar (UC 2409$ vs DH $2244). The incre-
mental analysis pointed out for each gained Qaly in DH
a cost-saving of $1068. The cost-utility ratio for integra-
tion of Day Hospital to manage chronic heart failure was
$19,462(13,904–34,048). CONCLUSIONS: heart failure
management program delivered by day-hospital can
reduce mortality and morbidity of CHF patients. This
management strategy is cost-effective and has an equi-
table cost from a society point of view.
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OBJECTIVE: To study the incidence and cost of man-
agement of deep vein thrombosis (DVT), and to estimate
the cost avoidance due to prophylactic therapy in a group
of Hong Kong Chinese patients undergoing total hip
replacement (THR). METHOD: All Chinese patients
undergoing THR from November 98 to December 2001
at the Prince of Wales Hospital in Hong Kong were ret-
rospectively evaluated. In those patients who developed
DVT, the cost of management was estimated by identify-
ing the total healthcare resources used. The cost avoid-
ance of DVT by using prophylactic low-molecular-weight
heparin LMWH (nandroparin calcium) was estimated by
construction of a decision tree model. Sensitivity analysis
was performed to examine whether the results were
robust to changes in the key variables. The study was per-
formed from the perspective of a publicly funded hospi-
tal. RESULTS: A total of 90 Chinese patients underwent
THR surgery over the study period and their baseline
characteristics were comparable. Six had symptomatic
DVT, yet only three were conﬁrmed by Doppler ultra-
sonography. The incidence of symptomatic DVT in this
group of Hong Kong Chinese was therefore 3.33%. 
The treatment costs after THR surgery with or without
DVT per patient were HKD129,980 (119,740–
140,210) (median (25%,75%)) (1USD = 7.8HKD) and
HKD79,410 (73,860–84,960) respectively. The cost of
management of DVT without prophylaxis was
HKD53,570 (39,980–67,170) per patient. A close to
70% reduction in cost was possible if LMWH prophy-
laxis was used. CONCLUSION: The incidence of symp-
tomatic DVT in the present group of Hong Kong Chinese
patients after THR surgery was similar to that in the 
Caucasians. According to the decision-tree model, cost
avoidance appears to be possible by using LMWH for
prophylaxis of DVT in high-risk orthopaedic procedures.
Prophylactic antithrombotic therapy should be consid-
ered for routine use in THR surgery.
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OBJECTIVE: Cost-effectiveness analysis of treatments 
to reduce cholesterol concentration, blood pressure and
smoking for the primary prevention of coronary heart
disease in Catalonia (Spain) was assessed in this study.
METHODS: Cost-effectiveness was measured in terms of
met cost per life year gained (LYG), comparing costs and
beneﬁts from coronary heart disease in individuals aged
>30 years with hypercholesterolemia >200mg/dl, moder-
ate/severe (DBP > 105mmHg) and mild (DBP 95–104
mmHg) hypertension and smoking. Cost-effectiveness
ratios were calculated for 1998 using a 5% discount rate.
RESULTS: Cost-effectiveness ratios obtained in this study
ranged from €2,608 to €8,058 per LYG for smoking ces-
sation therapies, from €7,061 to €81,027 per LYG for
moderate/severe hypertension treatment, from €10,877 to
€126,990 per LYG for mild hypertension treatment, and
from €12,792 to €142,910 per LYG for dietary and phar-
maceutical treatment of hypercholesterolemia. Incremen-
tal cost-effectiveness analysis showed that lovastatin
(HMG-CoA reductase inhibitor) was more cost-effective
than cholestyramine (bile acid sequestrant) and gemﬁ-
brozil (ﬁbrate) in individuals with hypercholesterolemia,
hydrochlorothiazide (diuretic) and propranolol (beta-
adrenergic antagonist) were more cost-effective than 
captopril (angiotensin-converting-enzyme inhibitor), 
prazosin (alpha-adrenergic antagonist) and nifedipine
(calcium channel blocker) in individuals with moder-
ate/severe hypertension treatment, and hydrochloroth-
iazide and nifedipine were more cost-effective than
propranolol, prazosin and captopril in individuals with
mild hypertension treatment. CONCLUSION: When
resources for the primary prevention of coronary heart
disease are limited, the priority order based on cost-
effectiveness analysis was smoking cessation, hyperten-
sion treatment and hypercholesterolemia treatment.
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OBJECTIVES: To evaluate the pharmacoeconomics of
hawthorn-extract treatment of CHF at stage NYHA II, 
a prospective 3-year observational study has been con-
ducted since summer 1999. A cost-utility-analysis (CUA)
will compare hawthorn treatment (WS 1442 as mono- 
or add-on-therapy) to any other treatment option. The
results of two years of study conduct are presented.
METHODS: Open, non-randomized observational
cohort study with matched-pairs evaluation. The ﬁrst
cohort (Hawthorn-Cohort, HC) comprises patients
receiving hawthorn-extract therapy of CHF. In the second
cohort (Conventional-Cohort, CC) patients without
hawthorn but any other treatment were observed. In 217
study centres 952 patients were included (HC: 588; CC:
364). A number of 116 pairs were determined as sample
size necessary for evaluation. For measuring HRQL the
EuroQoL-5D was used. Matching criteria were derived
from demographic factors and clinical diagnosis. The per-
spective of the German statutory health insurance funds
was applied. RESULTS: 130 pairs could be established
under consideration of two-year data. Median direct costs
per year for HC amounted to €473 and for CC to €449.
This difference is not signiﬁcant (p = .218). Most impor-
